분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-06-14 22:45:47 , Hit : 1158
 CRISPR Antidotes Galore

The Scientist » News & Opinion » Daily News
Anti-CRISPR proteins are prevalent in phage genomes and bacterial mobile genetic elements, researchers show.

By Anna Azvolinsky | June 13, 2016

Diverse groups of bacterial species encode genes that block the activity of specific CRISPR/Cas systems, according to a team from the University of Toronto and the University of Otago, New Zealand. Scanning prophages (genomes of bacteriophages integrated within bacterial genomes), Toronto’s Alan Davidson and colleagues have identified five new protein-coding anti-CRISPR genes, adding to the list of nine his group had previously identified. The team’s latest work, published today (June 13) in Nature Microbiology, highlights a way to learn how CRISPR systems work as well as a potential add-on tool for CRISPR-based gene editing.

“The authors report a beautiful application of the Red Queen theory, which posits that there is a kind of an arms race between all living organisms, and between the host and parasite in particular,” said Didier Raoult, a microbiologist at Aix-Marseille University in France who was not involved in the work. These proteins “are the phages’ answers to bacterial CRISPR systems which are a form of aggression by the bacteria,” he added.

“The discovery of anti-CRISPR proteins is not surprising in the sense that phage must develop these as part of the nature of the host-parasite co-evolution,” said Eugene Koonin of the US National Center for Biotechnology Information and the National Library of Medicine.

Davidson’s team in 2013 found that a single prophage within the Pseudomonas aeruginosa genome conferred resistance to a host of other types of phages. So the researchers tweaked the P. aeruginosa CRISPR systems to try to understand how the prophage might affect the bacterium’s susceptibility to phage infection. They found that P. aeruginosa’s type I-F CRISPR system only prevented infection by certain types of phage. Searching within the phage genomes, the researchers found five unique genes, each with anti-CRISPR activity. In a subsequent study, the researchers identified another four genes the showed activity against type I-E CRISPR in P. aeruginosa.

For the present study, Davidson’s team broadened its search to the genomes of species within the diverse Proteobacteria phylum. Because the nine previously identified proteins had no sequence motifs in common, the researchers searched for sequences with homology to a putative transcriptional regulator gene they found adjacent to all known anti-CRISPR loci.

Davidson and colleagues then tested whether each putative anti-CRISPR gene, expressed on a plasmid, could support the ability of phage to replicate within bacteria with either a type I-E and I-F CRISPR system targeting the phage. The group identified four more anti-CRISPR genes targeting the I-F system, plus one that is able to block the activity of both type I-F and I-E CRISPR systems.

“That there are a lot of different anti-CRISPR gene families emphasizes that these genes are advantageous to a phage and that the CRISPR system poses an important barrier to phage replication,” Davidson told The Scientist. All three of the anti-CRISPR proteins the team previously tested in vitro bound and blocked CRISPR function in a distinct way.

According to Raoult, these anti-CRISPR proteins may provide a clue as to why some bacterial and archaeal species retain foreign DNA elements (such as prophages and other mobile genetic elements) that encode for resistance genes, while others do not. “This is an important question,” said Raoult. “I suspect that one difference may be these anti-CRISPR proteins.”

Anti-CRISPR proteins may also be useful experimental tools. “It’s not difficult to imagine that these proteins could be used to modulate the activity of CRISPR systems for genomic editing and engineering in the same way that Cas9 mutants are now being used, or as a way to transiently regulate the expression of CRISPR,” said Koonin.

The Toronto-led team is now working on identifying more genes against other CRISPR systems, including the widely used CRISPR/Cas9.

“This is probably just the tip of the proverbial iceberg of the total number of anti-CRISPR proteins,” Koonin told The Scientist.  

A. Pawluk et al., “Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species,” Nature Microbiology, doi:10.1038/nmicrobiol.2016.85, 2016.







1107   혁신적인 폐암 면역치료제를 승인한 FDA  이성욱 2015/10/06 1147
1106   5년새 20배 성장 `유전자치료제` 시장..경쟁력 확보 필수  이성욱 2016/07/21 1148
1105   혈액 암과 면역세포의 DNA 편집의 관계  이성욱 2015/09/14 1151
1104   프리온 질환을 막는 유전자 돌연변이  이성욱 2015/06/15 1156
  CRISPR Antidotes Galore  이성욱 2016/06/14 1158
1102   [바이오토픽] Science, 2017년 과학연구 총결산  이성욱 2017/12/27 1162
1101   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1166
1100   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1167
1099   진화와 질병치료 연구를 진전시킬 새로운 유전 메커니즘  이성욱 2015/02/06 1167
1098   Using RNA to Amplify RNA  이성욱 2016/08/16 1167
1097   GSK Gets Positive CHMP Opinion For Strimvelis To Treat Rare Disease ADA-SCID  이성욱 2016/04/02 1170
1096   네안데르탈인과 이웃에 살았던 현생인류의 두개골 발견  이성욱 2015/02/03 1172
1095   CRISPR Encodes Movie into Bacteria, Then DNA Sequencing Plays It  이성욱 2017/07/14 1173
1094   microRNA가 췌장암 치료제가 될 수 있을까  이성욱 2015/06/30 1175
1093   JPM서 논란 ‘유전자가위 기술’ 올해의 마일스톤은?  이성욱 2018/01/21 1176
1092   중증 근이영양증을 치료하는 RNA 편집 기술  이성욱 2015/10/15 1177
1091   알츠하이머 질환에 대한 항체약물의 가능성  이성욱 2015/07/30 1179
1090   지방간과 흉터가 유전과 관련되어 있다?  이성욱 2015/10/05 1182
1089   옥스포드 나노포어, 휴대용 시퀀서 미니온 출시 임박  이성욱 2015/05/08 1186
1088   부모의 특징을 자식에게 전달하는 방식: 박테리아의 DNA  이성욱 2015/02/19 1187

[1][2][3][4][5][6][7][8] 9 [10]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN